PCI Biotech to present at Bio-Europe Spring 2018

Oslo, Norway, March 12, 2018 PCI Biotech (OSE:PCIB), a clinical-stage company
developing innovative therapeutics that address significant unmet medical needs,
today announced that it will present at Bio-Europe Spring 2018 being held March
12-14, 2018 at the Amsterdam RAI Convention Center, Amsterdam, The Netherlands.

On Wednesday, March 14, 2018 at 10:15am (CET), Mr. Gaël L'Hévéder, CBDO, will
present an overview of PCI Biotech's technology and the multiple business
development and commercial opportunities available based on this proprietary
platform. The presentation will be made available on PCI Biotech's website
(www.pcibiotech.com ) under "Other presentations".

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform.  PCI is
applied to three distinct anticancer paradigms: fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead fimaChem programme consists of a clinical Phase I/II clinical
study in bile duct cancer, an orphan indication with a high unmet need and
without approved products. fimaVacc applies a unique mode of action to enhance
the essential cytotoxic effect of therapeutic cancer vaccines, which works in
synergy with several other state-of-the-art vaccination technologies. fimaNAc
utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
www.pcibiotech.com
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757.

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.


This information is subject to the disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.